^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Adenosine A2A receptor antagonist

    Related drugs:
    Apply
    INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors (NCT04580485)
    Phase 1
    Incyte Corporation
    Completed
    Last update posted :
    02/18/2025
    Initiation :
    02/03/2021
    Primary completion :
    01/22/2024
    Completion :
    01/22/2024
    CD8
    |
    Zynyz (retifanlimab-dlwr) • INCB106385
    A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer (NCT06116786)
    Phase 1
    Johnson & Johnson Enterprise Innovation Inc.
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    11/27/2023
    Primary completion :
    04/14/2027
    Completion :
    06/07/2029
    EGFR • BRAF • ALK • ROS1
    |
    EGFR mutation
    |
    cetrelimab (JNJ-63723283)
    A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma (NCT05335941)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    02/10/2025
    Initiation :
    06/13/2023
    Primary completion :
    09/30/2025
    Completion :
    09/30/2025
    MTAP • IL17A
    |
    pemetrexed • Yutuo (zimberelimab) • etrumadenant (AB928)
    Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer (ARC-7) (NCT04262856)
    Phase 2
    Arcus Biosciences, Inc.
    Active, not recruiting
    Last update posted :
    05/24/2024
    Initiation :
    05/28/2020
    Primary completion :
    02/01/2025
    Completion :
    02/01/2025
    PD-L1
    |
    PD-L1 expression • PD-L1 overexpression
    |
    Yutuo (zimberelimab) • domvanalimab (AB154) • etrumadenant (AB928) • mitazalimab (ADC-1013)
    A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies (ARC-2) (NCT03719326)
    Phase 1
    Arcus Biosciences, Inc.
    Completed
    Last update posted :
    05/24/2024
    Initiation :
    10/15/2018
    Primary completion :
    07/01/2021
    Completion :
    07/02/2021
    HER-2 • ER • PGR
    |
    HER-2 negative • ER negative • PGR negative
    |
    albumin-bound paclitaxel • pegylated liposomal doxorubicin • eganelisib (IPI-549) • etrumadenant (AB928) • doxorubicin liposomal
    A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer (ARC-4) (NCT03846310)
    Phase 1
    Arcus Biosciences, Inc.
    Active, not recruiting
    Last update posted :
    05/24/2024
    Initiation :
    04/01/2019
    Primary completion :
    08/01/2024
    Completion :
    08/01/2024
    EGFR
    |
    EGFR mutation
    |
    Keytruda (pembrolizumab) • carboplatin • pemetrexed • Yutuo (zimberelimab) • etrumadenant (AB928)
    A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies (NCT05955105)
    Phase 1/2
    Innolake Biopharm
    Recruiting
    Last update posted :
    05/21/2024
    Initiation :
    07/25/2023
    Primary completion :
    01/25/2026
    Completion :
    07/24/2026
    PD-L1 • TMB • MSI • CD8 • CD68
    |
    PD-L1 expression
    |
    Loqtorzi (toripalimab-tpzi) • ILB-2109
    Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer (NCT04791839)
    Phase 2
    Washington University School of Medicine
    Active, not recruiting
    Last update posted :
    04/09/2024
    Initiation :
    08/04/2021
    Primary completion :
    01/31/2025
    Completion :
    04/30/2029
    PD-L1
    |
    PD-L1 expression
    |
    Yutuo (zimberelimab) • domvanalimab (AB154) • etrumadenant (AB928)
    CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers (NCT03454451)
    Phase 1
    Corvus Pharmaceuticals, Inc.
    Completed
    Last update posted :
    12/21/2023
    Initiation :
    04/25/2018
    Primary completion :
    12/28/2022
    Completion :
    02/19/2023
    MSI
    |
    Keytruda (pembrolizumab) • ciforadenant (CPI-444) • mupadolimab (CPI-006)
    A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies (NCT02740985)
    Phase 1
    AstraZeneca
    Completed
    Last update posted :
    05/26/2023
    Initiation :
    06/17/2016
    Primary completion :
    12/31/2020
    Completion :
    03/31/2023
    EGFR • ALK
    |
    EGFR mutation • MSI-H/dMMR • ALK rearrangement
    |
    Imfinzi (durvalumab) • docetaxel • Xtandi (enzalutamide) • abiraterone acetate • dexamethasone • oleclumab (MEDI9447) • imaradenant (AZD4635)
    Trial of PBF-509 and PDR001 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) (AdenONCO) (NCT02403193)
    Phase 1
    Palobiofarma SL
    Completed
    Last update posted :
    01/12/2022
    Initiation :
    10/01/2015
    Primary completion :
    10/01/2021
    Completion :
    11/24/2021
    EGFR • ALK
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • ALK positive • ALK rearrangement
    |
    spartalizumab (PDR001) • taminadenant (NIR178)